soul trial oral semaglutide cardiovascular outcomes 2024 nejm results π Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no Semaglutide cardiovascular outcomes align more
Pay in 4 interest-free payments of $6.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 16 - Oct 21






.png?w=1280&max-h=720&fit=crop&auto=format)













